TAK · Takeda Pharmaceutical Company L
$20.43
+0.94% last session
End-of-day data · close of 2026-10-26
Market cap
$65B
Enterprise value
$5,140B
Trailing P/E
—
Forward P/E
38.2
Dividend yield
3.0%
Beta
0.10
Avg volume
3M
Employees
47K
Daily Change %
0.94%
5 Days Change
3.51%
10 Days Change
9.94%
30 Days Change
8.24%
60 Days Change
11.62%
Month to Day Change
14.00%
Year to Day Change
30.60%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — TAK
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Signal Summary as of 2026-10-26
- bearish: RSI (14): RSI is 72 — overbought territory; the recent run-up may be due for a pause.
- bullish: Price vs 50-day MA: Trading 9.5% above the 50-day MA ($18.65).
- bullish: Price vs 200-day MA: Trading 16.9% above the 200-day MA ($17.47).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.16) — short-term momentum is improving.
- bullish: 52-week range: Price is within 5% of the 52-week high ($20.43).
TAK Price Chart
Loading chart for TAK…
Fundamentals
About Takeda Pharmaceutical Company L
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.
More in Drug Manufacturers - Specialty & Generic
TEVA
Teva Pharmaceutical Industries
$46B 28.8% YTD
HLN
Haleon plc
$45B 4.6% YTD
ZTS
Zoetis Inc.
$33B -33.8% YTD
UTHR
United Therapeutics Corporation
$25B 20.0% YTD
VTRS
Viatris Inc.
$21B 51.9% YTD
NBIX
Neurocrine Biosciences, Inc.
$15B 1.0% YTD
ELAN
Elanco Animal Health Incorporat
$11B 0.3% YTD
RDY
Dr. Reddy's Laboratories Ltd
$11B -5.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.